



**INTERNATIONAL JOURNAL OF
PHARMACEUTICAL SCIENCES**
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: <https://www.ijpsjournal.com>



Mini Review Article

A Review on the Potential Interaction Between Pyridostigmine and Glimepiride

Gudladona Raghava Ravali*, M Durga Bhavani

Sri Raghavendra College of Pharmacy, Bangalore, Karnataka, India

ARTICLE INFO

Published: 16 Sept 2025

Keywords:

Drug–drug interactions;

Pyridostigmine;

Glimepiride;

Hypoglycaemia; Myasthenia
gravis; Antidiabetic therapy

DOI:

10.5281/zenodo.17136131

ABSTRACT

Drug–drug interactions are an important concern in patients receiving multiple therapies, especially when treatments for chronic conditions overlap. Pyridostigmine [4,5,6], a cholinesterase inhibitor used in myasthenia gravis, and glimepiride [1,2,3,7], a sulfonylurea antidiabetic, are rarely studied together. Interaction checkers list this combination as a “possible risk,” mainly due to the potential for enhanced hypoglycaemia, but the evidence behind this warning is weak. In this review, we explain why doctors might be cautious about using pyridostigmine and glimepiride together, summarize what has been reported so far, and point out the important questions that research still hasn’t answered.

INTRODUCTION

Patients with neuromuscular disorders such as myasthenia gravis may also suffer from type 2 diabetes, especially with increasing age. This raises the possibility of concurrent use of pyridostigmine [4,5,6] and glimepiride [1,2,3,7]. While no strong clinical reports confirm a dangerous interaction, online drug-interaction tools often flag this pair as a “moderate risk.” The problem is that these warnings are not backed by solid clinical studies. This paper reviews what is

currently known, the theoretical concerns, and where further research is needed.

2. Pharmacology of the Two Drugs

- Pyridostigmine [4,5,6]: A reversible acetylcholinesterase inhibitor. By increasing acetylcholine at neuromuscular junctions, it improves muscle strength in myasthenia gravis. Its main side effects are cholinergic—abdominal cramps, diarrhoea, sweating, and sometimes bradycardia.
- Glimepiride [1,2,3,7]: A sulfonylurea that lowers blood glucose by stimulating

***Corresponding Author:** Gudladona Raghava Ravali

Address: Sri Raghavendra College of Pharmacy, Bangalore, Karnataka, India

Email ✉: raghava7389@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.



pancreatic beta-cell insulin release. Its major adverse effect is hypoglycaemia, particularly if meals are missed or doses are too high.

3. Theoretical Basis for Interaction

Pharmacokinetically, there is no significant overlap—pyridostigmine [4,5,6] is not metabolized by the liver to any major extent, whereas glimepiride [1,2,3,7] is largely metabolized by CYP2C9 [2,3,7]. So, metabolism is not the issue.

The concern is pharmacodynamic. Pyridostigmine [4,5,6] can increase vagal tone, which may indirectly enhance insulin release or worsen hypoglycaemic episodes triggered by glimepiride [1,2,3,7]. Add to that the possibility that cholinergic side effects—like sweating, dizziness, or fatigue—can mimic or mask hypoglycaemia, making detection harder for patients.

4. What the Evidence Says

At present, very little real-world data exists:

- Case reports: None clearly describing a pyridostigmine [4,5,6]–glimepiride [1,2,3,7] interaction were found.
- Clinical studies: No trials have tested this drug pair in humans.
- Interaction databases: Most online checkers (e.g., Drugs.com, Medscape) classify the combination as a “possible” or “moderate” interaction, but the supporting references are vague or absent.

In short, the cautionary label seems to be based more on theory than on clinical evidence.

5. Why This Matters Clinically

Even without hard data, patients on both drugs deserve careful monitoring. Hypoglycaemia remains the most serious concern—especially in elderly patients, those with irregular eating habits, or those on other antidiabetic medications.

A practical step for clinicians is to educate patients about recognizing and managing low blood sugar. If pyridostigmine [4,5,6] is added to a diabetic patient’s regimen, closer glucose monitoring may be justified.

6. Areas Needing More Study

At this point, what stands out most is how little we actually know. The caution about combining pyridostigmine [4,5,6] and glimepiride [1,2,3,7] is mostly theoretical, and there are no strong studies to confirm it. To move forward, a few things are especially important:

- Real-world studies: We need clinical trials or at least follow-up studies that track patients who are taking both medicines, so we can see if the risk of hypoglycaemia is real.
- Safety database analysis: Large reporting systems like FAERS or WHO Vigibase should be examined more closely to check whether patients on this combination are showing more cases of low blood sugar.
- Mechanistic work: Basic science studies, whether in labs or animal models, could help explain if pyridostigmine [4,5,6] has any meaningful effect on blood sugar control or insulin release.




Figure 1. Proposed interaction between pyridostigmine and glimepiride.




Figure 2. Mechanism of pyridostigmine.




Figure 3. Mechanism of glimepiride.




Figure 4. Areas needing more study regarding pyridostigmine–glimepiride interaction.

CONCLUSION

Right now, the evidence for an interaction between pyridostigmine [4,5,6] and glimepiride [1,2,3,7] is more theoretical than proven. While most interaction checkers err on the side of caution, no convincing clinical studies confirm the risk. Until stronger data emerge, clinicians should remain alert, educate patients about hypoglycaemia, and monitor carefully when these drugs are co-prescribed.

REFERENCES

1. Pharmaceuticals. The Clinical Pharmacokinetics and Pharmacodynamics of Glimepiride — A Systematic Review and Meta-Analysis. 2025;18(1):122. doi:10.3390/ph18010122.
2. Pharmacogenet Genomics. CYP2C9 and OATP1B1 Genetic Polymorphisms Affect the Metabolism and Transport of Glimepiride and Gliclazide. 2018;28(8):195–205. doi:10.1097/FPC.0000000000000346.
3. Clin Pharmacol Ther. Glyburide and Glimepiride Pharmacokinetics in Subjects with

- Different CYP2C9 Genotypes. 2005;78(1):90–98. doi:10.1016/j.clpt.2005.03.008.
4. Int J Obes Relat Metab Disord. Cholinergic Enhancement by Pyridostigmine Increases the Insulin Response to Glucose Load in Obese Patients but Not in Normal Subjects. 1997;21(12):1111-4. doi:10.1038/sj.ijo.0800523.
5. Eur J Clin Pharmacol. Pharmacokinetics and Oral Bioavailability of Pyridostigmine in Man. 1980;18:423-8.
6. Clin Pharmacokinet. Renal Clearance of Pyridostigmine in Patients with Myasthenia Gravis. 1968;13(5):298-304.
7. Pak J Zool. A Cohort Study on Response of T2DM Patients to Oral Antidiabetics and Their Association with CYP2C9*3 Gene Polymorphism (rs1057910) in Khyber Pakhtunkhwa, Pakistan. 2024;20(1):100-36. doi:10.17582/journal.pjz/20231226112338.

HOW TO CITE: Gudladona Raghava Ravali, M Durga Bhavani, A Review on the Potential Interaction Between Pyridostigmine and Glimepiride, *Int. J. of Pharm. Sci.*, 2025, Vol 3, Issue 9, 1773-1776. <https://doi.org/10.5281/zenodo.17136131>

